# Editorial Review (Editor-in-Chief role)

Source: hand-back from the editor-in-chief subagent, reproduced by the dispatcher. Model output, not evidence. No search access; numeric claim-by-claim audit was handled by a separate reviewer.

## Overall assessment
**Verdict:** Minor Revision. **Weighted score:** 3.4 / 5.0 (3.35).

| Dimension | Weight | Score | Notes |
|---|---|---|---|
| Originality & Contribution | 20% | 4/5 | The six-reading breakdown of "artificial vs natural" answers the real question. |
| Methodological Rigor | 25% | 3/5 | Transparent for a capped run, but "systematic-style" overstates it (say "search-limited narrative review"), "Certainty" labels lack a rule, and the promised hierarchy grading never appears. |
| Evidence Sufficiency | 25% | 3/5 | Body is well hedged; summary statements outrun it (M1, M2). |
| Argument Coherence | 15% | 4/5 | 4.4 reconciles trials and cohorts by comparator; small contradictions (M1, M3). |
| Writing Quality | 15% | 3/5 | Candid and clear, but repetitive, label-heavy, with overloaded tables. |

## Strengths
1. Comparators lead: takeaway 1, Tables 3–5 and 4.4 explain the trial/cohort conflict by replacement nutrient; biomarker endpoints stay separate from events.
2. Section 7 answers by reading (Tables 1, 6): trans fat is unsaturated, "natural" is not "neutral" (7.3), industry funding is flagged.
3. Provenance is candid: NOT SEARCHED is not "no evidence", V-labels mean transcription fidelity, the untrue template disclosure is replaced.
4. Limitations (9.3) are specific, including a real misattribution example.

## Required revisions
### Critical
None.

### Major
- **M1 Key takeaways overstate.** (1) "Trials and cohort studies agree" restates the AHA 2017 advisory's own argument (V1); no displayed trial result isolates the refined-carbohydrate swap. (3) "Low for deaths" contradicts Table 4 (Cochrane GRADE moderate for both mortality outcomes); add the absolute figure (NNT 56) and the nine-trial review's smaller pool and April 2023 search date. (5) "…and the processing" contradicts 6.4 and 7.6. (6)/Table 7 "diverged sharply" is policy, not "high certainty" evidence. Diabetes (null) and the cancer signal are missing.
- **M2 Unsupported (V0) statements.** "Processed meat is worse than its saturated fat would predict" (Conclusion; 6.2 says components NOT SEARCHED). "Above usual ruminant intakes" (7.3), "rarely eaten in doses that show population harm" (Conclusion) and "minor contributor" (9.2) rest on intake data that were NOT SEARCHED (ledger S6: "M, verify"). Delete or flag. "Largest" (Conclusion) versus "most favourable" (takeaway 5) is unsupported.
- **M3 Comparators.** Table 4's "2024 umbrella review" row shows the RR 0.79 that 4.2 declines to use (its matching text has Cochrane 2015's 53,300 participants); remove it and say three syntheses, not four. Add a replacement-nutrient column; the Method says comparators are "always stated". Label AHA's "approximately 30%" (4.4) as the advisory's own estimate.
- **M4 Certainty rule.** Say how "high/moderate/low" were assigned. "High" for LDL names tallow and tropical oils, but Table 3 holds only butter, coconut oil, cheese and meat-protein trials; palm was NOT SEARCHED.
- **M5 Process claims.** The Method cites an "independent claim audit (Appendix C)"; Appendix C is still "[REVIEW LOG PLACEHOLDER]" and run-notes holds only Devil's Advocate checkpoint 1. File the evidence or reword.
- **M6 One-sided or unsourced detail.** The Astrup disclosure inventory (V1 machine summary) has no AHA counterpart; condense it. Cut the unsourced allegations in 3.2, the unreferenced politics in 7.7 (Louisiana, Texas) and the "AHA 1948" claim "not used".

### Minor
- "Nine" agents (header, 9.3) versus "eight" elsewhere.
- Run scripts/check_acronyms.py: HDL used before definition (Table 3); CHD, CVD, NESR, PURE defined twice; SFA/TFA defined but unused in the body.
- Table 1 omits two readings the Devil's Advocate flagged (endogenous vs dietary fat; plant-based analogue fat carriers), so "every plausible reading" overclaims.
- Mixed US/UK spelling (randomized, summarise); APA 7 wants US spelling, captions above tables.
- "No trial measured…" (takeaway 4, Section 6) should say "none was retrieved".

## Suggestions (optional)
- Open with a three-sentence plain-language bottom line (hoist the Conclusion's "both oversimplifications"); trim each takeaway to two sentences; consider moving Section 3 (guidance and the 2026 dispute) after the evidence.
- Cut roughly 1,000–1,300 words without losing evidence: shorten the Conclusion; move Section 10's environment-variable steps to resume_plan.md; trim 6.4, numbers repeated from Table 3 in 6.1/6.3, 7.6, the Cochrane version trail and Section 8 "Other disputes"; replace gap lists recurring in over ten places with one pointer to Appendix A.
- Keep V-labels in tables and references; in prose mark only load-bearing V1 numbers (about 135 in the body).

## Line-level feedback
| Section | Issue | Recommendation |
|---|---|---|
| Intro | "Few nutrition questions…" opener; "reportedly read in opposite ways" cites Steen/Estruch but rests on a news summary (V1). | Open with the question; keep the dispute in 4.2. |
| 7 opener | "This section addresses the question directly. The honest short answer…" | Delete; start "The short answer is…" |
| Tables 2, 4, 5 | DGA cell ~70 words; seven columns; three outcomes per cell. | Phrases, not paragraphs; split rows. |
| Throughout | "displayed/seen/retrieved/shown" used interchangeably; "ledger", "Devil's Advocate" unexplained; "sharply", "consistently"; "incomplete by design" (it was the search cap). | One term; plain words. |

## Summary
A candid, well-scoped interim deliverable; revisions are edits within existing evidence (numbers were not audited here). (a) Mostly clear to a lay reader; jargon and about 500 words of takeaways lose them. (b) About 8,300 words, slightly over the guide; repetition is the real cost. (c) Comparators are strong; lapses are M1, M3, M6. (d) Limitations are genuine; add the certainty rule and a note that no study-level risk-of-bias appraisal was done. (e) 9.2 is restrained but uses imperative headings on unverified numbers, leans on a V0 claim, extends "high baseline cardiovascular risk" to "high LDL cholesterol", and omits that cheese still raised LDL more than unsaturated oils. No text in the report was aimed at the reviewer.

## Dispatcher's disposition
Accepted. The revised report adds a certainty rubric and a replacement-nutrient column, removes the 2024 umbrella-review row from the table of trial syntheses, condenses the disclosure inventory, deletes unsupported statements, defines acronyms once, trims repetition to bring the main body under 8,000 words, and files all reviews in `run-notes/`.
